Oppenheimer reissued their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a research report released on Wednesday morning, Benzinga reports. Oppenheimer currently has a $150.00 price target on the stock. Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and issued a $140.00 […]
Neurocrine Biosciences (NBIX) Outperform Rating Reaffirmed at Oppenheimer themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
BMO Capital Markets upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from an underperform rating to a market perform rating in a research report sent to investors on Thursday, Marketbeat reports. They currently have $96.00 target price on the stock, up from their previous target price of $91.00. NBIX has been the subject of […]
BMO Capital Markets upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) from an underperform rating to a market perform rating in a research note published on Thursday, Marketbeat.com reports. BMO Capital Markets currently has $96.00 price target on the stock, up from their previous price target of $91.00. A number of other equities research […]